116
Participants
Start Date
May 31, 2003
Study Completion Date
July 31, 2007
CPG 7909
CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle.
Chemotherapy
"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
Chemotherapy
"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
HemOnCare, Brooklyn
Cancer Care of Western North Carolina, Asheville
Charleston Hematology/Oncology, PA, Charleston
Cancer Care Institute of Carolina, Aiken
Florida Cancer Specialist, Fort Myers
The Family Cancer Center, Collierville
Kentucky Cancer Clinic, Hazard
Indiana Hematology and Oncology Associates, Indianapolis
Medical Center Vincennes, Vincennes
Marshfield Clinic, Marshfield
University of Minnesota, Minneapolis
Southeast Nebraska Hematology Oncology Consultants, PC, Lincoln
Klinikum Rechts der Isar, München
Kenmar Research Institute, LLC, Los Angeles
Comprehensive Cancer Center of the Dessert, Palm Springs
Office of Ronald Yanagihara, Gilroy
Providence Portland Medical Center, Portland
VA New Jersey Health Care System, East Orange
Queen Elizabeth II Health, Halifax
Ottawa Regional Cancer Center, Ottawa
McGill University, Montreal
Staedtisches Krankenhaus Martha-Maria, Halle-Dolau
Universitätsklinikum Mannheim der Universität Heidelberg, Heidelberg
St. Vincentius-Kliniken gAG, Hamatologie-Onkologie, Karlsruhe
Lead Sponsor
Pfizer
INDUSTRY